There were 519 press releases posted in the last 24 hours and 431,875 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image